BDMD$2.98
$2.89
Chart
Performance
Key Stats
AI BDMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldBaird Medical Investment Holdings Limited exhibits mixed signals. While showing strong profitability and revenue growth in its latest reported periods, the company has experienced a significant stock price decline. Current technical indicators are largely bearish, suggesting caution. The long-term outlook depends on its ability to stabilize its stock performance and maintain profitability.
Thematic
Baird Medical operates in the medical device sector, focusing on ablation technologies for tumor treatment. The increasing global prevalence of cancer and advancements in minimally invasive procedures present a positive thematic backdrop. However, its market position and competitive landscape will be key determinants of its success within this theme.
Fundamental
Baird Medical shows robust profitability and revenue growth in its most recent annual reports (2021-2024). However, the sharp decline in its stock price over the past year (-81.49%) indicates significant market concerns or a re-rating. While the balance sheet appears solid with increasing assets and manageable liabilities, the negative free cash flow in the latest period is a concern.
Technical
The stock has experienced a severe price decline, trading significantly below its 52-week high. Technical indicators across multiple timeframes (1m, 5m, 15m, 30m, 1h, 2h, 4h, 1d) predominantly signal 'Sell' or 'Neutral' for moving averages and oscillators, indicating strong downward momentum.
| Factor | Score |
|---|---|
| Medical Device Innovation | 70 |
| Healthcare Market Growth | 75 |
| Competitive Landscape | 50 |
| Emerging Markets Focus | 65 |
| Regulatory Environment (Medical Devices) | 50 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 85 |
| Growth | 75 |
| Balance Sheet Health | 60 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 15 |
| Momentum | 25 |
| Volume Confirmation | 35 |
| Support & Resistance | 40 |
| Short-Term Oscillators | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Improving Profitability
Net income has grown from $10.09M in Q4 2021 to $12.45M in Q4 2024, showing a consistent upward trend in profitability.
Attractive P/E Ratio
The trailing P/E ratio of 4.16 is significantly lower than the sector average, suggesting the stock may be undervalued relative to its earnings.
Bearish Points (8)
Significant Recent Decline
The stock has experienced substantial negative performance over various periods, including -47.69% in the last month and -81.49% over the past year, indicating significant investor concern or market headwinds.
High P/S Ratio
The trailing P/S ratio of 7.6 (based on 2024 annual data, implied) is considerably high, suggesting that the market is valuing the company's revenue at a premium, which might be unsustainable if growth falters.
Calendar
May 2025
16
Next Earnings Date
H: $
A: $
L: $
Profile
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; long microwave ablation needles; and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, as well as soft tissue ablation. It sells its products through third-party distributors. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
A leading clinical-stage gene editing company, directly comparable in the advanced therapies space focused on genetic diseases, overlapping with BDMD's regenerative medicine focus.
Weight: 90
Major biotech company with significant investments and partnerships in gene editing and gene therapy, including a leading CRISPR program, highly relevant to advanced therapies.
Weight: 88
Specializes in gene therapies for severe genetic diseases, making it a direct peer in the highly specialized and evolving field of cell and gene therapies.
Weight: 87
A clinical-stage genome editing company utilizing CRISPR/Cas9, operating in the cutting-edge area of genetic medicine alongside BDMD's focus.